PAVE in Latin America: Introduction and Updates

November 14, 2023

Elodie Jambert, MMV
Jamil Barton, PATH
PAVE is an umbrella for MMV / PATH supported *P. vivax* initiatives

PAVE facilitates access to new and existing malaria diagnostics and treatments for *P. vivax* elimination.

Our goal is to support countries in accelerating the elimination of *P. vivax* malaria.

PAVE supports countries in achieving their elimination goals through:

- working with National Malaria Programmes to identify optimal radical cure tool options and strategies for their given contexts to achieve higher patient coverage.
- generating and making available high-quality evidence on *P. vivax* case management that can be considered by national governments in making policy decisions and guiding implementation.
- advancing the development of quality-assured, child-friendly treatments for relapse prevention.
PAVE is working to ensure access to G6PD testing, tafenoquine, and primaquine for adults and children across *P. vivax* endemic countries. PAVE is accomplishing this through engagement with NMCPs to increase knowledge of tools, support policy change, procurement, and roll-out of products.

PAVE is also supporting feasibility studies and operational research looking at the best way to use these tools at different levels of the healthcare system in endemic countries.

PAVE is engaging stakeholders at various levels in more than 15 countries across the major *P. vivax* endemic regions.
PAVE Priority Countries

![Map of PAVE Priority Countries](image)

- **PAVE Priority Countries:**
  - Ethiopia
  - Lao PDR
  - Vietnam
  - Indonesia
  - PNG
  - Peru
  - Brazil
  - India
  - Thailand
  - PNG

- **PAVE Feasibility Studies/Operational Research**
- **Scale-Up**
- **Market Entry**
- **Strategy Creation**
- **Launch Planning**
- **Market Landscaping**
- **PAVE Priority Countries**

- **PAVE Priority Countries**
  - Ethiopia
  - Lao PDR
  - Vietnam
  - Indonesia
  - PNG
  - Peru
  - Brazil
  - India
  - Thailand

- **Map Legend:**
  - Scale-Up
  - Market Entry
  - Strategy Creation
  - Launch Planning
  - Market Landscaping
  - PAVE Feasibility Studies/Operational Research
PAVE progress towards scale-up

Market Landscaping

14 country landscapes completed
- Brazil, Cambodia, Colombia, Ethiopia, Indonesia, Lao PDR, Myanmar, Pakistan, Papua New Guinea, Peru, Thailand, Sudan, Venezuela, Vietnam

Strategy Creation

7 readiness workshops held
- Myanmar, Lao PDR, Vietnam, Cambodia, Peru
- Pakistan and PNG (readiness workshop managed by APMEN VxWG)

Launch Planning

7 TQ & PQ Feasibility studies in process
- TQ: Brazil (completed), Thailand and Peru (ongoing), Ethiopia and Vietnam (planned)
- PQ: Indonesia, PNG (planned)

Market Entry

2 countries initiating G6PD introduction
- Thailand (G6PD & PQ), Vietnam (planned intro in 2023 w/ G6PD & PQ)

Scale up

2 countries scaling radical cure & G6PD Dx
- Cambodia (G6PD & PQ) Lao PDR (G6PD & PQ)

Qn-G6PD studies completed or in process

- 3 Qn-G6PD studies completed or in process
  - Lao PDR (G6PD & PQ)
  - Vietnam (G6PD & PQ)
  - Colombia (G6PD training)

Peru – TQ in EML; G6PD and TQ policy adoption in progress (Q4 ’23) ahead of feasibility study

Brazil – CONITEC approval paves way for national adoption
PAVE Activities and Milestones in Latin America, 2022 & 2023

**BRAZIL**
- Feasibility study, G6PD + TQ/PQ
- Health Economic Studies
- Dossier for the inclusion of new tools into the Brazil’s Single Health System (SUS)
- Formal Introduction of new tools into the Brazil’s Single Health System (SUS) with CONITEC approval

**COLOMBIA**
- Launch of Pilot Education Program (PEP)
- Economic Health Studies
- Finalization of the PEP
- Pilot implementation of G6PD testing
- Signed MoU between MSPS, MMV and PATH

**GUATEMALA, HONDURAS y PANAMÁ**
- Evaluation of Case Management for *P. vivax*
- Health Registration for new tools
- Pilot implementation of G6PD testing
- Multi-year planning for the adoption of new tools

**PERU**
- Inclusion of TQ into the Essential Medicines List
- Update of National Treatment Guidelines
- Health Economic Studies
- Feasibility study, G6PD + TQ/PQ

Partnership for Vivax Elimination
The way forward

- **Technical Support** for partners interested in developing malaria elimination interventions
- Completion of and access to *training and educational materials* from PAVE projects
- **PAVE Regional Meetings** in 2024 and 2025
- Advancing Access to *pediatric formulations of radical cure* (pTQ and pPQ)
- Completion and dissemination of *Peru’s Feasibility Study* results
- Regular updates and exchange with key actors in Latin America’s malaria ecosystem, especially National Malaria Programs and international partners
Gracias

We would additionally like to acknowledge all our donors for their support.
## Estados Regulatorios

<table>
<thead>
<tr>
<th>País</th>
<th>Cura Radical (0.25g/kg)</th>
<th>Registro Sanitario</th>
<th>Guías de Práctica Clínica</th>
<th>Lista de Medicamentos Esenciales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brasil</td>
<td>PQ7d</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Colombia</td>
<td>PQ14d</td>
<td>✓</td>
<td>✓ En marcha</td>
<td>✓ _ _</td>
</tr>
<tr>
<td>Guatemala</td>
<td>PQ14d</td>
<td>✓ En marcha</td>
<td>_</td>
<td>_ _ _</td>
</tr>
<tr>
<td>Honduras</td>
<td>PQ14d / PQ7d</td>
<td>✓ En marcha</td>
<td>_</td>
<td>_ _ _</td>
</tr>
<tr>
<td>Panamá</td>
<td>PQ14d / PQ7d</td>
<td>✓ En marcha</td>
<td>_</td>
<td>_ _ _</td>
</tr>
<tr>
<td>Perú</td>
<td>PQ7d</td>
<td>✓</td>
<td>✓ En marcha</td>
<td>✓</td>
</tr>
</tbody>
</table>

### TQ

- FDA de EEUU: Jul 2018
- TGA de Australia: Sep 2018
- TGA de Australia: Mar 2022 (pediátrica)
- WHO Pre-qualification: en marcha

### STANDARD Diagnóstico Biosensor (SDB)

- TGA de Australia: Abr 2021
- ERPD con GF hasta 2024
- WHO Pre-qualification: en marcha